@article{07b72c49b8314d21b296c818820a744a,
title = "Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer",
author = "Sena, \{Laura A.\} and Tingchang Wang and Hao Wang and Markowski, \{Mark C.\} and Antonarakis, \{Emmanuel S.\} and Denmeade, \{Samuel R.\}",
note = "Funding Information: We thank the patients and caregivers who participated in the clinical trial described. This project was supported by the National Institutes of Health , USA ( NIH ) grants P30CA006973 and 1R01CA184012-01. Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ESA is a paid consultant/adviser to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, Lilly, Bayer, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson \& Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of an AR-V7 biomarker technology that has been licensed to Qiagen. S.R.D. has received research funding to his institution from Astellas. M.C.M. is a paid consultant to Clovis and Exelixis. Other authors declare no conflicts of interest.We thank the patients and caregivers who participated in the clinical trial described. This project was supported by the National Institutes of Health, USA (NIH) grants P30CA006973 and 1R01CA184012-01.",
year = "2023",
month = mar,
doi = "10.1016/j.ejca.2022.12.001",
language = "English (US)",
volume = "181",
pages = "23--25",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
}